New owners in Calliditas Therapeutics
International specialist investors Sofinnova Partners and Vivo Capital acquire 6% in Calliditas Therapeutics AB from Industrifonden and Investinor.
– We welcome Sofinnova Partners and Vivo Capital to the ownership group of Calliditas. We believe that these investors will contribute substantially to the further development of the Company. Industrifonden and Investinor will continue to be among the largest shareholders of Calliditas, and we both share a deepfelt conviction of the Company’s future potential, said Ann-Tove Kongsnes, Investment Director at Investinor.